Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Cash from Financing Activities for 6 consecutive years, with $108.6 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 8.91% to $108.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $108.5 million through Dec 2025, up 4.82% year-over-year, with the annual reading at $108.5 million for FY2025, 4.82% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $108.6 million at Inhibikase Therapeutics, up from -$134130.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $108.6 million in Q4 2025, with the low at -$409662.0 in Q1 2021.
  • Average Cash from Financing Activities over 5 years is $17.4 million, with a median of $31771.0 recorded in 2025.
  • Peak annual rise in Cash from Financing Activities hit 1692893.51% in 2021, while the deepest fall reached 263.79% in 2021.
  • Over 5 years, Cash from Financing Activities stood at $29892.0 in 2021, then crashed by 785.03% to -$204769.0 in 2022, then soared by 32.56% to -$138104.0 in 2023, then skyrocketed by 72280.72% to $99.7 million in 2024, then increased by 8.91% to $108.6 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $108.6 million, -$134130.0, and $31771.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.